 | • レポートコード：MRC2306A023 • 出版社/出版日：Persistence Market Research / 2023年3月 • レポート形態：英文、PDF、394ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User License | ￥735,000 (USD4,900) | ▷ お問い合わせ |
| Multi User License | ￥1,140,000 (USD7,600) | ▷ お問い合わせ |
| Corporate License | ￥1,590,000 (USD10,600) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Persistence Market Research社発行の当調査レポートでは、世界の膀胱がん治療薬市場の現状について調査・分析し、エグゼクティブサマリー、市場概要、主要市場動向、価格分析、需要分析・予測、市場背景、市場構造分析、競争分析、仮定、調査手法などの構成でまとめております。セグメント分析では、がん種類別（筋層非浸潤性膀胱がん、筋層浸潤性膀胱がん）分析、悪性度別（低悪性度膀胱がん、高悪性度膀胱がん）分析、治療薬種類別（免疫療法、カルメットゲリン桿菌、アベルマブ、ニボルマブ、その他）分析、化学療法別（マイトマイシンC、ドセタキセル、パクリタキセル、シスプラチン、その他）分析、地域別（北米、中南米、ヨーロッパ、東アジア、南アジア、オセアニア、中東・アフリカ）分析などの項目を掲載しています。なお、当市場の主要企業には、Pfizer Inc.、Merck KGaA、Merck & Co、AstraZeneca PLC、Roche Holding AG（Genentech）、Astellas Pharma Inc.、J&J（Janssen Biotech）、Cipla Inc.、Amneal Pharma、Bristol Myers Squibb Co.、Dr. Reddy’s Laboratories, Inc.、Gilead Sciences Inc.、Endo Pharma、UroGen Pharma, Inc.などが含まれています。 ・エグゼクティブサマリー ・市場概要 ・主要市場動向 ・価格分析 ・需要分析・予測 ・市場背景 ・世界の膀胱がん治療薬市場規模：がん種類別 - 筋層非浸潤性膀胱がんの市場規模 - 筋層浸潤性膀胱がんの市場規模 ・世界の膀胱がん治療薬市場規模：悪性度別 - 低悪性度膀胱がんの市場規模 - 高悪性度膀胱がんの市場規模 ・世界の膀胱がん治療薬市場規模：治療薬種類別 - 免疫療法の市場規模 - カルメットゲリン桿菌の市場規模 - アベルマブの市場規模 - ニボルマブの市場規模 - その他治療薬種類の市場規模 ・世界の膀胱がん治療薬市場規模：化学療法分析 - マイトマイシンCの市場規模 - ドセタキセルの市場規模 - パクリタキセルの市場規模 - シスプラチンの市場規模 - その他化学療法の市場規模 ・世界の膀胱がん治療薬市場規模：地域別 - 北米の膀胱がん治療薬市場規模 - 中南米の膀胱がん治療薬市場規模 - ヨーロッパの膀胱がん治療薬市場規模 - 東アジアの膀胱がん治療薬市場規模 - 南アジアの膀胱がん治療薬市場規模 - オセアニアの膀胱がん治療薬市場規模 - 中東・アフリカの膀胱がん治療薬市場規模 ・市場構造分析 ・競争分析 ・仮定 ・調査方法 |
Bladder Cancer Treatment Drugs Market – Report Scope
The latest publication by Persistence Market Research on the global bladder cancer treatment drugs market evaluates the opportunities and current market landscape and provides detailed analysis and updates about corresponding sections affecting the market. The study offers detailed insights into current market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2023 to 2033.
Important indicators for the successful growth of the market are presented in this comprehensive report, which includes a Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described exhaustively in Persistence Market Research’s study. This research study can support readers to know the demand for bladder cancer treatment drugs and the quantitative development opportunities during the study period.
The research is beneficial for shareholders in the landscape, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the bladder cancer treatment drugs market. Insights and information presented in this Persistence Market Research study can be leveraged by shareholders in the bladder cancer treatment drugs market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.
Market statistics, as well as information linked to the macro- as well as macroeconomic variables affecting the business scenario in the bladder cancer treatment drugs market, are also included in the current study. Depending on potential developments in the market, substantive insights are also encountered in this report. Additionally, by the data submitted in this report, minor companies and new entrants in the industry can be aided in making suitable company choices to achieve traction in the market.
Key Market Segments
Persistence Market Research’s study on the bladder cancer treatment drugs market offers information divided into five important segments – cancer type, cancer grade, drug type, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Cancer Type
Non-Muscle-Invasive Bladder Cancer
Muscle-Invasive Bladder Cancer
Cancer Grade
Low-Grade Bladder Cancer
High-Grade Bladder Cancer
Drug Type
Immunotherapy
Bacillus Calmette-Guerin
Avelumab
Nivolumab
Pembrolizumab
Others
Chemotherapy
Mitomycin C
Docetaxel
Paclitaxel
Cisplatin
Others
Targeted Therapy
Erdafitinib
Enfortumab vedotin-ejfv
Sacituzumab govitecan
Others
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Specialty Pharmacies
Online Pharmacies
Region
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa
Key Questions Answered in Study
Which regions will continue to remain the most profitable markets for bladder cancer treatment drug manufacturers over the coming years?
How will changing trends impact the market?
How has the COVID-19 crisis impacted market growth?
How can market players capture the low-hanging opportunities in developed regions?
What are the strategies of stakeholders in the market to shape their position in this landscape?
What are the restraining factors that investors need to be aware of and might tackle while investing in the market?
What are the developmental trends that will impact the market?
How can companies in the bladder cancer treatment drugs market avail themselves of the growth opportunities in developed and emerging sectors?
Research Methodology
In Persistence Market Research’s study, a unique research methodology is utilized to conduct extensive research on the growth of the bladder cancer treatment drugs market and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts to ensure the accuracy and reliability of the conclusions.
Secondary resources referred to by analysts during the production of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.
Comprehensive information acquired from primary and secondary resources acts as validation from companies in the market and makes Persistence Market Research’s projections on the growth prospects of the bladder cancer treatment drugs market more accurate and reliable.
レポート目次1. Executive Summary
1.1. Global Market Outlook
1.2. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Key Market Trends
3.1. Key Trends Impacting the Market
4. Key Success Factors
4.1. Product Adoption Analysis
4.2. Key Strategies, by Manufacturers
4.3. Regulatory Scenario
4.4. Porters Analysis
4.5. PESTLE Analysis
4.6. Supply Chain Analysis
4.7. Funding In Research & Development
4.8. Clinical Trials Analysis
4.9. Pipeline Analysis
4.10. Disease Epidemiology, by Region
4.11. Reimbursement Scenario
4.12. Parent Market Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Pharmaceutical Industry Overview
5.2. Forecast Factors – Relevance & Impact
5.2.1. Rising Healthcare Spending
5.2.2. Increasing Prevalence of Cancer
5.2.3. Increasing Awareness and Supportive Government Initiatives
5.2.4. Increase in Funding for
5.2.5. Cancer Research
5.2.6. Increase In Product Launches
5.2.7. Strong Product Pipeline
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis – Impact Assessment
6.1.1. Impact of COVID-19 – 2021 Market Scenario
6.1.2. COVID-19 Impact Summary
7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2012-2022 and Forecast, 2023-2033
7.1. Historical Market Value (US$ Mn) Analysis, 2012-2022
7.2. Current and Future Market Value (US$ Mn) Projections, 2023-2033
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2012-2022 and Forecast 2023-2033, by Bladder Cancer Type
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis by Bladder Cancer Type, 2012-2022
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Bladder Cancer Type, 2023-2033
8.3.1. Non-Muscle-Invasive Bladder Cancer
8.3.2. Muscle-Invasive Bladder Cancer
8.4. Market Attractiveness Analysis by Bladder Cancer Type
9. Global Market Analysis 2012-2022 and Forecast 2023-2033, by Cancer grade
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis by Cancer grade, 2012-2022
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Cancer grade, 2023-2033
9.3.1. Low-grade bladder cancer
9.3.2. High-grade bladder cancer
9.4. Market Attractiveness Analysis by Cancer grade
10. Global Market Analysis 2012-2022 and Forecast 2023-2033, by Drug Type
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis by Drug Type, 2012-2022
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Drug Type, 2023-2033
10.3.1. Immunotherapy
10.3.1.1. Bacillus Calmette-Guerin
10.3.1.2. Avelumab
10.3.1.3. Nivolumab
10.3.1.4. Pembrolizumab
10.3.1.5. Others
10.3.2. Chemotherapy
10.3.2.1. Mitomycin C
10.3.2.2. Docetaxel
10.3.2.3. Paclitaxel
10.3.2.4. Cisplatin
10.3.2.5. Others
10.3.3. Targeted therapy
10.3.3.1. Erdafitinib
10.3.3.2. Enfortumab vedotin-ejfv
10.3.3.3. Sacituzumab govitecan
10.3.3.4. Others
10.4. Market Attractiveness Analysis by Drug Type
11. Global Market Analysis 2012-2022 and Forecast 2023-2033, by Distribution Channel
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2022
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2023-2033
11.3.1. Hospital Pharmacy
11.3.2. Retail Pharmacy
11.3.3. Specialty Pharmacy
11.3.4. Online Pharmacy
11.4. Market Attractiveness Analysis By Distribution Channel
12. Global Market Analysis 2012-2022 and Forecast 2023-2033, by Region
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis By Region, 2012-2022
12.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2023-2033
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. East Asia
12.3.5. South Asia
12.3.6. Oceania
12.3.7. Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis By Region
13. North America Market Analysis 2012-2022 and Forecast 2023-2033
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Analysis, By Market Taxonomy, 2012-2022
13.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy 2023-2033
13.3.1. By Country
13.3.1.1. U.S.
13.3.1.2. Canada
13.3.2. By Bladder Cancer Type
13.3.3. By Cancer Grade
13.3.4. By Drug Type
13.3.5. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Bladder Cancer Type
13.4.3. By Cancer Grade
13.4.4. By Drug Type
13.4.5. By Distribution Channel
13.5. Key Market Participants – Intensity Mapping
13.6. Drivers and Restraints – Impact Analysis
13.7. Country-Level Analysis & Forecast
13.7.1. U.S. Market Analysis
13.7.1.1. .Introduction
13.7.1.2. Market Analysis and Forecast by Market Taxonomy
13.7.1.2.1. By Bladder Cancer Type
13.7.1.2.2. By Cancer Grade
13.7.1.2.3. By Drug Type
13.7.1.2.4. By Distribution Channel
13.7.2. Canada Market Analysis
13.7.2.1. Introduction
13.7.2.2. Market Analysis and Forecast by Market Taxonomy
13.7.2.2.1. By Bladder Cancer Type
13.7.2.2.2. By Cancer Grade
13.7.2.2.3. By Drug Type
13.7.2.2.4. By Distribution Channel
14. Latin America Market Analysis 2012-2022 and Forecast 2023-2033
14.1. Introduction
14.2. Historical Market Size (US$ Mn) and Trend Analysis By Market Taxonomy, 2012-2022
14.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033
14.3.1. By Country
14.3.1.1. Mexico
14.3.1.2. Brazil
14.3.1.3. Argentina
14.3.1.4. Rest of Latin America
14.3.2. By Bladder Cancer Type
14.3.3. By Cancer Grade
14.3.4. By Drug Type
14.3.5. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Bladder Cancer Type
14.4.3. By Cancer Grade
14.4.4. By Drug Type
14.4.5. By Distribution Channel
14.5. Key Market Participants – Intensity Mapping
14.6. Drivers and Restraints – Impact Analysis
14.7. Country-Level Analysis & Forecast
14.7.1. Mexico Market Analysis
14.7.1.1. Introduction
14.7.1.2. Market Analysis and Forecast by Market Taxonomy
14.7.1.2.1. By Bladder Cancer Type
14.7.1.2.2. By Cancer Grade
14.7.1.2.3. By Drug Type
14.7.1.2.4. By Distribution Channel
14.7.2. Brazil Market Analysis
14.7.2.1. Introduction
14.7.2.2. Market Analysis and Forecast by Market Taxonomy
14.7.2.2.1. By Bladder Cancer Type
14.7.2.2.2. By Cancer Grade
14.7.2.2.3. By Drug Type
14.7.2.2.4. By Distribution Channel
14.7.3. Argentina Market Analysis
14.7.3.1. Introduction
14.7.3.2. Market Analysis and Forecast by Market Taxonomy
14.7.3.2.1. By Bladder Cancer Type
14.7.3.2.2. By Cancer Grade
14.7.3.2.3. By Drug Type
14.7.3.2.4. By Distribution Channel
15. Europe Market Analysis 2012-2022 and Forecast 2023-2033
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Analysis, By Market Taxonomy, 2012-2022
15.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. Italy
15.3.1.3. France
15.3.1.4. U.K.
15.3.1.5. Spain
15.3.1.6. Poland
15.3.1.7. Russia
15.3.1.8. Rest of Europe
15.3.2. By Bladder Cancer Type
15.3.3. By Cancer Grade
15.3.4. By Drug Type
15.3.5. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Bladder Cancer Type
15.4.3. By Cancer Grade
15.4.4. By Drug Type
15.4.5. By Distribution Channel
15.5. Key Market Participants – Intensity Mapping
15.6. Drivers and Restraints – Impact Analysis
15.7. Country-Level Analysis & Forecast
15.7.1. Germany Market Analysis
15.7.1.1. Introduction
15.7.1.2. Market Analysis and Forecast by Market Taxonomy
15.7.1.2.1. By Bladder Cancer Type
15.7.1.2.2. By Cancer Grade
15.7.1.2.3. By Drug Type
15.7.1.2.4. By Distribution Channel
15.7.2. Italy Market Analysis
15.7.2.1. Introduction
15.7.2.2. Market Analysis and Forecast by Market Taxonomy
15.7.2.2.1. By Bladder Cancer Type
15.7.2.2.2. By Cancer Grade
15.7.2.2.3. By Drug Type
15.7.2.2.4. By Distribution Channel
15.7.3. France Market Analysis
15.7.3.1. Introduction
15.7.3.2. Market Analysis and Forecast by Market Taxonomy
15.7.3.2.1. By Bladder Cancer Type
15.7.3.2.2. By Cancer Grade
15.7.3.2.3. By Drug Type
15.7.3.2.4. By Distribution Channel
15.7.4. U.K. Market Analysis
15.7.4.1. Introduction
15.7.4.2. Market Analysis and Forecast by Market Taxonomy
15.7.4.2.1. By Bladder Cancer Type
15.7.4.2.2. By Cancer Grade
15.7.4.2.3. By Drug Type
15.7.4.2.4. By Distribution Channel
15.7.5. Spain Market Analysis
15.7.5.1. Introduction
15.7.5.2. Market Analysis and Forecast by Market Taxonomy
15.7.5.2.1. By Bladder Cancer Type
15.7.5.2.2. By Cancer Grade
15.7.5.2.3. By Drug Type
15.7.5.2.4. By Distribution Channel
15.7.6. Poland Market Analysis
15.7.6.1. Introduction
15.7.6.2. Market Analysis and Forecast by Market Taxonomy
15.7.6.2.1. By Bladder Cancer Type
15.7.6.2.2. By Cancer Grade
15.7.6.2.3. By Drug Type
15.7.6.2.4. By Distribution Channel
15.7.7. Russia Market Analysis
15.7.7.1. Introduction
15.7.7.2. Market Analysis and Forecast by Market Taxonomy
15.7.7.2.1. By Bladder Cancer Type
15.7.7.2.2. By Cancer Grade
15.7.7.2.3. By Drug Type
15.7.7.2.4. By Distribution Channel
16. South Asia Market Analysis 2012-2022 and Forecast 2023-2033
16.1. Introduction
16.2. Historical Market Size (US$ Mn) and Trend Analysis By Market Taxonomy, 2012-2022
16.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033
16.3.1. By Country
16.3.1.1. India
16.3.1.2. Indonesia
16.3.1.3. Malaysia
16.3.1.4. Thailand
16.3.1.5. Rest of South Asia
16.3.2. By Bladder Cancer Type
16.3.3. By Cancer Grade
16.3.4. By Drug Type
16.3.5. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Bladder Cancer Type
16.4.3. By Cancer Grade
16.4.4. By Drug Type
16.4.5. By Distribution Channel
16.5. Key Market Participants – Intensity Mapping
16.6. Drivers and Restraints – Impact Analysis
16.7. Country-Level Analysis & Forecast
16.7.1. India Market Analysis
16.7.1.1. Introduction
16.7.1.2. Market Analysis and Forecast by Market Taxonomy
16.7.1.2.1. By Bladder Cancer Type
16.7.1.2.2. By Cancer Grade
16.7.1.2.3. By Drug Type
16.7.1.2.4. By Distribution Channel
16.7.2. Indonesia Market Analysis
16.7.2.1. Introduction
16.7.2.2. Market Analysis and Forecast by Market Taxonomy
16.7.2.2.1. By Bladder Cancer Type
16.7.2.2.2. By Cancer Grade
16.7.2.2.3. By Drug Type
16.7.2.2.4. By Distribution Channel
16.7.3. Malaysia Market Analysis
16.7.3.1. Introduction
16.7.3.2. Market Analysis and Forecast by Market Taxonomy
16.7.3.2.1. By Bladder Cancer Type
16.7.3.2.2. By Cancer Grade
16.7.3.2.3. By Drug Type
16.7.3.2.4. By Distribution Channel
16.7.4. Thailand Market Analysis
16.7.4.1. Introduction
16.7.4.2. Market Analysis and Forecast by Market Taxonomy
16.7.4.2.1. By Bladder Cancer Type
16.7.4.2.2. By Cancer Grade
16.7.4.2.3. By Drug Type
16.7.4.2.4. By Distribution Channel
17. East Asia Market Analysis 2012-2022 and Forecast 2023-2033
17.1. Introduction
17.2. Historical Market Size (US$ Mn) and Trend Analysis By Market Taxonomy, 2012-2022
17.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033
17.3.1. By Country
17.3.1.1. China
17.3.1.2. Japan
17.3.1.3. South Korea
17.3.2. By Bladder Cancer Type
17.3.3. By Cancer Grade
17.3.4. By Drug Type
17.3.5. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Bladder Cancer Type
17.4.3. By Cancer Grade
17.4.4. By Drug Type
17.4.5. By Distribution Channel
17.5. Key Market Participants – Intensity Mapping
17.6. Drivers and Restraints – Impact Analysis
17.7. Country-Level Analysis & Forecast
17.7.1. China Market Analysis
17.7.1.1. Introduction
17.7.1.2. Market Analysis and Forecast by Market Taxonomy
17.7.1.2.1. By Bladder Cancer Type
17.7.1.2.2. By Cancer Grade
17.7.1.2.3. By Drug Type
17.7.1.2.4. By Distribution Channel
17.7.2. Japan Market Analysis
17.7.2.1. Introduction
17.7.2.2. Market Analysis and Forecast by Market Taxonomy
17.7.2.2.1. By Bladder Cancer Type
17.7.2.2.2. By Cancer Grade
17.7.2.2.3. By Drug Type
17.7.2.2.4. By Distribution Channel
17.7.3. South Korea Drugs Market Analysis
17.7.3.1. Introduction
17.7.3.2. Market Analysis and Forecast by Market Taxonomy
17.7.3.2.1. By Bladder Cancer Type
17.7.3.2.2. By Cancer Grade
17.7.3.2.3. By Drug Type
17.7.3.2.4. By Distribution Channel
18. Oceania Market 2012-2022 and Forecast 2022-2033
18.1. Introduction
18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2012-2022
18.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033
18.3.1. By Country
18.3.1.1. Australia
18.3.1.2. New Zealand
18.3.2. By Bladder Cancer Type
18.3.3. By Cancer Grade
18.3.4. By Drug Type
18.3.5. By Distribution Channel
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Bladder Cancer Type
18.4.3. By Cancer Grade
18.4.4. By Drug Type
18.4.5. By Distribution Channel
18.5. Key Market Participants – Intensity Mapping
18.6. Drivers and Restraints – Impact Analysis
18.7. Country-Level Analysis & Forecast
18.7.1. Australia Market Analysis
18.7.1.1. Introduction
18.7.1.2. Market Analysis and Forecast by Market Taxonomy
18.7.1.2.1. By Bladder Cancer Type
18.7.1.2.2. By Cancer Grade
18.7.1.2.3. By Drug Type
18.7.1.2.4. By Distribution Channel
18.7.2. New Zealand Market Analysis
18.7.2.1. Introduction
18.7.2.2. Market Analysis and Forecast by Market Taxonomy
18.7.2.2.1. By Bladder Cancer Type
18.7.2.2.2. By Cancer Grade
18.7.2.2.3. By Drug Type
18.7.2.2.4. By Distribution Channel
19. Middle East and Africa (MEA) Market Analysis 2012-2022 and Forecast 2023-2033
19.1. Introduction
19.2. Historical Market Size (US$ Mn) and Trend Analysis By Market Taxonomy, 2012-2022
19.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033
19.3.1. By Country
19.3.1.1. GCC Countries
19.3.1.2. South Africa
19.3.1.3. North Africa
19.3.1.4. Türkiye
19.3.1.5. Rest of Middle East and Africa
19.3.2. By Bladder Cancer Type
19.3.3. By Cancer Grade
19.3.4. By Drug Type
19.3.5. By Distribution Channel
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Bladder Cancer Type
19.4.3. By Cancer Grade
19.4.4. By Drug Type
19.4.5. By Distribution Channel
19.5. Key Market Participants – Intensity Mapping
19.6. Drivers and Restraints – Impact Analysis
19.7. Country-Level Analysis & Forecast
19.7.1. GCC Countries Market Analysis
19.7.1.1. Introduction
19.7.1.2. Market Analysis and Forecast by Market Taxonomy
19.7.1.2.1. By Bladder Cancer Type
19.7.1.2.2. By Cancer Grade
19.7.1.2.3. By Drug Type
19.7.1.2.4. By Distribution Channel
19.7.2. South Africa Market Analysis
19.7.2.1. Introduction
19.7.2.2. Market Analysis and Forecast by Market Taxonomy
19.7.2.2.1. By Bladder Cancer Type
19.7.2.2.2. By Cancer Grade
19.7.2.2.3. By Drug Type
19.7.2.2.4. By Distribution Channel
19.7.3. North Africa Market Analysis
19.7.3.1. Introduction
19.7.3.2. Market Analysis and Forecast by Market Taxonomy
19.7.3.2.1. By Bladder Cancer Type
19.7.3.2.2. By Cancer Grade
19.7.3.2.3. By Drug Type
19.7.3.2.4. By Distribution Channel
19.7.4. Türkiye Market Analysis
19.7.4.1. Introduction
19.7.4.2. Market Analysis and Forecast by Market Taxonomy
19.7.4.2.1. By Bladder Cancer Type
19.7.4.2.2. By Cancer Grade
19.7.4.2.3. By Drug Type
19.7.4.2.4. By Distribution Channel
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies
20.2. Market Share Analysis of Top Players
20.3. Market Presence Analysis
20.3.1. By Regional footprint of Players
20.3.2. Product footprint by Players
20.3.3. Channel Foot Print by Players
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive [Tentative list]
21.3.1. Pfizer Inc.
21.3.1.1. Overview
21.3.1.2. Product Portfolio
21.3.1.3. Business Segment Overview
21.3.1.4. Sales Footprint
21.3.1.5. SWOT Analysis
21.3.1.6. Key Financials
21.3.1.7. Strategy Overview
21.3.2. Merck KGaA
21.3.2.1. Overview
21.3.2.2. Product Portfolio
21.3.2.3. Business Segment Overview
21.3.2.4. Sales Footprint
21.3.2.5. SWOT Analysis
21.3.2.6. Key Financials
21.3.2.7. Strategy Overview
21.3.3. Merck & Co
21.3.3.1. Overview
21.3.3.2. Product Portfolio
21.3.3.3. Business Segment Overview
21.3.3.4. Sales Footprint
21.3.3.5. SWOT Analysis
21.3.3.6. Key Financials
21.3.3.7. Strategy Overview
21.3.4. AstraZeneca PLC
21.3.4.1. Overview
21.3.4.2. Product Portfolio
21.3.4.3. Business Segment Overview
21.3.4.4. Sales Footprint
21.3.4.5. SWOT Analysis
21.3.4.6. Key Financials
21.3.4.7. Strategy Overview
21.3.5. Roche Holding AG (Genentech)
21.3.5.1. Overview
21.3.5.2. Product Portfolio
21.3.5.3. Business Segment Overview
21.3.5.4. Sales Footprint
21.3.5.5. SWOT Analysis
21.3.5.6. Key Financials
21.3.5.7. Strategy Overview
21.3.6. Astellas Pharma Inc.
21.3.6.1. Overview
21.3.6.2. Product Portfolio
21.3.6.3. Business Segment Overview
21.3.6.4. Sales Footprint
21.3.6.5. SWOT Analysis
21.3.6.6. Key Financials
21.3.6.7. Strategy Overview
21.3.7. J&J (Janssen Biotech)
21.3.7.1. Overview
21.3.7.2. Product Portfolio
21.3.7.3. Business Segment Overview
21.3.7.4. Sales Footprint
21.3.7.5. SWOT Analysis
21.3.7.6. Key Financials
21.3.7.7. Strategy Overview
21.3.8. Cipla Inc.
21.3.8.1. Overview
21.3.8.2. Product Portfolio
21.3.8.3. Business Segment Overview
21.3.8.4. Sales Footprint
21.3.8.5. SWOT Analysis
21.3.8.6. Key Financials
21.3.8.7. Strategy Overview
21.3.9. Amneal Pharma
21.3.9.1. Overview
21.3.9.2. Product Portfolio
21.3.9.3. Business Segment Overview
21.3.9.4. Sales Footprint
21.3.9.5. SWOT Analysis
21.3.9.6. Key Financials
21.3.9.7. Strategy Overview
21.3.10. Bristol Myers Squibb Co.
21.3.10.1. Overview
21.3.10.2. Product Portfolio
21.3.10.3. Business Segment Overview
21.3.10.4. Sales Footprint
21.3.10.5. SWOT Analysis
21.3.10.6. Key Financials
21.3.10.7. Strategy Overview
21.3.11. Dr. Reddy’s Laboratories, Inc.
21.3.11.1. Overview
21.3.11.2. Product Portfolio
21.3.11.3. Business Segment Overview
21.3.11.4. Sales Footprint
21.3.11.5. SWOT Analysis
21.3.11.6. Key Financials
21.3.11.7. Strategy Overview
21.3.12. Gilead Sciences Inc.
21.3.12.1. Overview
21.3.12.2. Product Portfolio
21.3.12.3. Business Segment Overview
21.3.12.4. Sales Footprint
21.3.12.5. SWOT Analysis
21.3.12.6. Key Financials
21.3.12.7. Strategy Overview
21.3.13. Endo Pharma
21.3.13.1. Overview
21.3.13.2. Product Portfolio
21.3.13.3. Business Segment Overview
21.3.13.4. Sales Footprint
21.3.13.5. SWOT Analysis
21.3.13.6. Key Financials
21.3.13.7. Strategy Overview
21.3.14. UroGen Pharma, Inc.
21.3.14.1. Overview
21.3.14.2. Product Portfolio
21.3.14.3. Business Segment Overview
21.3.14.4. Sales Footprint
21.3.14.5. SWOT Analysis
21.3.14.6. Key Financials
21.3.14.7. Strategy Overview
21.3.15. Teva Pharmaceuticals (Actavis)
21.3.15.1. Overview
21.3.15.2. Product Portfolio
21.3.15.3. Business Segment Overview
21.3.15.4. Sales Footprint
21.3.15.5. SWOT Analysis
21.3.15.6. Key Financials
21.3.15.7. Strategy Overview
21.3.16. Hikma Pharmaceuticals
21.3.16.1. Overview
21.3.16.2. Product Portfolio
21.3.16.3. Business Segment Overview
21.3.16.4. Sales Footprint
21.3.16.5. SWOT Analysis
21.3.16.6. Key Financials
21.3.16.7. Strategy Overview
21.3.17. Incyte
21.3.17.1. Overview
21.3.17.2. Product Portfolio
21.3.17.3. Business Segment Overview
21.3.17.4. Sales Footprint
21.3.17.5. SWOT Analysis
21.3.17.6. Key Financials
21.3.17.7. Strategy Overview
22. Assumptions and Acronyms Used
23. Research Methodology
Table 01: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer TypeTable 02: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type
Table 03: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade
Table 04: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade
Table 05: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type
Table 06: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type
Table 07: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel
Table 08: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel
Table 09: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Region
Table 10: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Region
Table 11: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country
Table 12: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country
Table 13: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type
Table 14: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type
Table 15: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade
Table 16: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade
Table 17: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type
Table 18: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type
Table 19: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel
Table 20: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel
Table 21: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country
Table 22: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country
Table 23: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type
Table 24: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type
Table 25: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade
Table 26: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade
Table 27: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type
Table 28: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type
Table 29: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel
Table 30: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel
Table 31: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country
Table 32: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country
Table 33: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type
Table 34: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type
Table 35: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade
Table 36: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade
Table 37: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type
Table 38: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type
Table 39: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel
Table 40: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel
Table 41: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country
Table 42: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country
Table 43: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type
Table 44: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type
Table 45: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade
Table 46: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade
Table 47: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type
Table 48: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type
Table 49: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel
Table 50: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel
Table 51: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country
Table 52: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country
Table 53: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type
Table 54: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type
Table 55: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade
Table 56: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade
Table 57: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type
Table 58: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type
Table 59: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel
Table 60: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel
Table 61: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country
Table 62: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country
Table 63: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type
Table 64: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type
Table 65: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade
Table 66: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade
Table 67: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type
Table 68: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type
Table 69: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel
Table 70: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel
Table 71: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country
Table 72: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country
Table 73: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type
Table 74: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type
Table 75: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade
Table 76: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade
Table 77: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type
Table 78: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type
Table 79: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel
Table 80: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel
